BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

APPENDIX 2

Schedule of enrolment, interventions and assessments, Group A + B

	STUDY PERIOD								
	Enrolment	Allocation	Post-allocation						
TIMEPOINT	**$-t_1$**	**0**	**t_1**	**t_2**	**t_3**	**t_4**	**t_5**	**t_6**	**t_7**
ENROLMENT:									
Eligibility screen	X								
Informed consent	X								
Questionnaire	X								
Allocation		X							
INTERVENTIONS:									
Continued RAS-inhibiting therapy			♦——	——	——	——	——	——	——♦
Discontinued RAS-inhibiting therapy			♦——	——	——	——	——	——	——♦
ASSESSMENTS:									
Basic Health Information			X						
Biochemistry Standard			X	X					
A-gas			X	X					
EWS			X	X					
Radiology			X		X				
Study Specific bio-samples			X			X			
Primary endpoint day 14							X		
Primary endpoint day 21								X	
Key Secondary endpoints					X				
Discharge					X				
30 days follow-up									X
AE					X				
Drop out					X				

$-t_1$ 0-48 hours before allocation
t_1 first 24 hours after allocation
t_2 thrice daily during admission
t_3 all available data during admission
t_4 weekly during admission
t_5 day 14
t_6 day 21
t_7 day 30

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Schedule of enrolment, interventions and assessments, Group C + D

	STUDY PERIOD							
	Enrolment	**Allocation**	**Post-allocation**					
TIMEPOINT	**$-t_1$**	**0**	**t_1**	**t_2**	**t_3**	**t_4**	**t_5**	**t_6**
ENROLMENT:								
Eligibility screen	X							
Informed consent	X							
Questionnaire	X							
Allocation		X						
INTERVENTIONS:								
Continued RAS-inhibiting therapy			♦—	—	—	—	—	—♦
Discontinued RAS-inhibiting therapy			♦—	—	—	—	—	—♦
ASSESSMENTS:								
Basic Health Information			X					
Biochemistry Standard			X	X	X	X	X	
EWS			X	X	X	X	X	
Study Specific bio-samples			X	X	X	X	X	
Primary endpoint day 14					X			
Primary endpoint day 21						X		
Key Secondary endpoints				X	X	X	X	X
30 days follow-up								X
AE				X	X	X	X	X
Drop out				X	X	X	X	X

$-t_1$ before allocation
t_1 first study visit, day 0
t_2 second study visit, day 7
t_3 third study visit, day 14
t_4 fourth study visit, day 21
t_5 fifth study visit, day 28
t_6 day 30